HIGH DOSES OF METHOTREXATE IN TREATMENT OF OSTEOGENIC SARCOMA PATIENTS

Palivets A.Y., A.G. Dedkov, V.S. Cherny, B.A. Tolstopyatov, G.I. Klimnyuk, S.I. Korovin, T.A. Tarasova

Reported are findings from treatment of 27 patients with long bone osteogenic sarcoma, stage ІІB. The treatment scheme included: 12 g/m2 of methotrexate , 120 mg/m2 of cisplatin (intraarterially), and 75 mg/m2 of doxorubicin. A high degree of therapeutic pathomorphosis was achieved in 81.5% patients. In this group, relapse-free 5-yearsurvivalratewas 59.2% andtotal 5-yearsurvivalrate was 70.4%. These results are considerably better compared to the control group which received methotrexate in a lower dose of 125 mg/m2 (35.7% and 40.5% respectively).